Zamerovimab  (Synonyms: CTB011; SYN023)

Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies^[1].

Zamerovimab (CTB011; SYN023) (0.001-100 μg/mL, 4 h) can induce cytotoxicity and promote viral clearance in a dose-dependent manner in CVS-infected BSR cells, also suggesting that cytotoxicity is associated with the specificity of cells expressing G proteins that are targeted by CTB011^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg, right gastrocnemius injection, once, 35 days) can increase the survival of Syrian hamsters infected with RABV BD06 virus in a dose-dependent manner, with survival rates of 58%, 83%, 100% and 100% at doses of 0.03, 0.1, 0.3 and 1.0 mg/kg, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2419087-87-7

[Zamerovimab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.  [Content Brief]